Sodium hyaluronate + placebo injection
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Symptomatic Hip Osteoarthritis
Conditions
Symptomatic Hip Osteoarthritis
Trial Timeline
Jan 1, 2005 → Mar 1, 2007
NCT ID
NCT00330135About Sodium hyaluronate + placebo injection
Sodium hyaluronate + placebo injection is a phase 3 stage product being developed by Daiichi Sankyo for Symptomatic Hip Osteoarthritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00330135. Target conditions include Symptomatic Hip Osteoarthritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00330135 | Phase 3 | Terminated |
Competing Products
20 competing products in Symptomatic Hip Osteoarthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ISV-305 | Sun Pharmaceutical | Phase 3 | 77 |
| rabeprazole sodium + Placebo | Eisai | Phase 3 | 77 |
| Verinurad + Febuxostat + Dapagliflozin | AstraZeneca | Phase 2 | 52 |
| RDEA3170 + Febuxostat + Benzbromarone | AstraZeneca | Phase 1/2 | 41 |
| Esomeprazole + Matching placebo | AstraZeneca | Phase 3 | 77 |
| DFV890 + Placebo | Novartis | Phase 2 | 52 |
| Omalizumab + Omalizumab + Placebo | Novartis | Phase 2 | 52 |
| Pasireotide + Octreotide | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 2 | 52 |
| valsartan | Novartis | Approved | 85 |
| Atorvastatin - Cholestyramine - Sitosterol | Pfizer | Pre-clinical | 22 |
| Epoetin biosimilar | Pfizer | Pre-clinical | 22 |
| Apixaban + Standard of care | Pfizer | Phase 3 | 76 |
| Azithromycin plus chloroquine | Pfizer | Phase 3 | 76 |
| Mavacamten | Bristol Myers Squibb | Approved | 84 |
| Aficamten + Placebo | Sanofi | Phase 3 | 76 |
| Vandetanib 300 mg | Sanofi | Pre-clinical | 22 |
| REGN7508 + Acetylsalicylic Acid (ASA) + Placebo | Regeneron Pharmaceuticals | Phase 3 | 76 |
| Rivaroxaban + Placebo | Bayer | Phase 3 | 74 |
| Droxidopa capsules + Placebo capsules | Lundbeck | Approved | 82 |